CD274 and pancreatic ductal adenocarcinoma: For instance, AK104 (PD-1+CTLA4) has been approved for platinum-refractory or metastatic cervical cancer, and KN046 (CD274+CTLA4) has entered Phase III clinical trials for pancreatic ductal adenocarcinoma (PDAC) and NSCLC.